Cardio-Oncology Considerations in Oncologic Treatment Decisions

At JADPRO Live Virtual 2021, presenter Anecita P. Fadol, PhD, FNP-BC, FAANP, FAAN, emphasized the critical role advanced practitioners play in the identification, monitoring, and management of the cardiac complications of cancer therapy. Dr. Fadol's presentation discussed identification of the...

Descripción completa

Detalles Bibliográficos
Autor principal: Fadol, Anecita P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Harborside Press LLC 2022
Materias:
Meeting Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9126328/
https://www.ncbi.nlm.nih.gov/pubmed/35663160
http://dx.doi.org/10.6004/jadpro.2022.13.3.11
_version_ 1784712102544408576
author Fadol, Anecita P.
author_facet Fadol, Anecita P.
author_sort Fadol, Anecita P.
collection PubMed
description At JADPRO Live Virtual 2021, presenter Anecita P. Fadol, PhD, FNP-BC, FAANP, FAAN, emphasized the critical role advanced practitioners play in the identification, monitoring, and management of the cardiac complications of cancer therapy. Dr. Fadol's presentation discussed identification of the most common cardiotoxicities associated with cancer therapy, clinical considerations related to common oncologic treatments with potential cardiotoxicity that may impact cancer treatment decisions, and the management of common cardiovascular issues in patients with cancer.
format Online
Article
Text
id pubmed-9126328
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Harborside Press LLC
record_format MEDLINE/PubMed
spelling pubmed-91263282022-06-04 Cardio-Oncology Considerations in Oncologic Treatment Decisions Fadol, Anecita P. J Adv Pract Oncol Meeting Reports At JADPRO Live Virtual 2021, presenter Anecita P. Fadol, PhD, FNP-BC, FAANP, FAAN, emphasized the critical role advanced practitioners play in the identification, monitoring, and management of the cardiac complications of cancer therapy. Dr. Fadol's presentation discussed identification of the most common cardiotoxicities associated with cancer therapy, clinical considerations related to common oncologic treatments with potential cardiotoxicity that may impact cancer treatment decisions, and the management of common cardiovascular issues in patients with cancer. Harborside Press LLC 2022-04 2022-05-23 /pmc/articles/PMC9126328/ /pubmed/35663160 http://dx.doi.org/10.6004/jadpro.2022.13.3.11 Text en © 2022 Harborside™ https://creativecommons.org/licenses/by-nc-nd/3.0/This article is distributed under the terms of the Creative Commons Attribution Non-Commercial Non-Derivative License, which permits unrestricted non-commercial and non-derivative use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Meeting Reports
Fadol, Anecita P.
Cardio-Oncology Considerations in Oncologic Treatment Decisions
title Cardio-Oncology Considerations in Oncologic Treatment Decisions
title_full Cardio-Oncology Considerations in Oncologic Treatment Decisions
title_fullStr Cardio-Oncology Considerations in Oncologic Treatment Decisions
title_full_unstemmed Cardio-Oncology Considerations in Oncologic Treatment Decisions
title_short Cardio-Oncology Considerations in Oncologic Treatment Decisions
title_sort cardio-oncology considerations in oncologic treatment decisions
topic Meeting Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9126328/
https://www.ncbi.nlm.nih.gov/pubmed/35663160
http://dx.doi.org/10.6004/jadpro.2022.13.3.11
work_keys_str_mv AT fadolanecitap cardiooncologyconsiderationsinoncologictreatmentdecisions

Ejemplares similares